Perifosine (** Generic name only (no approved brand names as it was not commercially approved) **)

Other Medications

1 Clinical Trials

Description

Perifosine has been investigated in clinical trials for its potential to inhibit Akt signaling and angiogenesis, with some studies suggesting it may have activity against colorectal cancer; however, it is not currently approved by the FDA or widely used in clinical practice for this indication. It was typically studied in combination with other agents such as capecitabine or cetuximab.

Mechanism of Action

Perifosine is a small molecule that acts as an inhibitor of Akt, a serine/threonine kinase involved in cell survival and proliferation pathways; it also has anti-angiogenic properties by inhibiting endothelial cell migration and tube formation.

Side Effects

Neutropenia; anemia; thrombocytopenia; nausea; vomiting; diarrhea; fatigue; rash; hyperglycemia

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT00398879 Phase 2
Archived
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
United States

Quick Info

Brand Name** Generic name only (no approved brand names as it was not commercially approved) **
CategoryOther Medications
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
771 trials
Leucovorin
Other Medications
631 trials
Trifluridine
Other Medications
45 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.